Abstract
In a double-blind study of 40 atopic allergic patients, injections of Human IgE Pentapeptide (HEPP) 2 mg in 0.5 ml buffer or 0.5 ml buffer (placebo) were given on days 1, 4, 8, 11, 15, 18, 22 and 25. Full clinical and laboratory data were collected before and at 25 days and clinical data at 8 and 15 days as well. Duplicate skin tests were made with 4 antigens and 3 controls and were repeated on days 9 and 25. All the laboratory tests were normal before and at 25 days with no difference between groups and no significant side-effects. Twelve of 23 who received HEPP improved clinically as against 4 of 15 controls (p<0.15). Skin tests showed significant differences (p<0.01) between the groups.
A comparable dose response study of 12 atopic patients (8 HEPP/4 Placebo) using six injections (2, 10, 20 and 100 mg) of HEPP revealed 20 mg to be a statistically significant (p<0.01) effective dose. We are presently completing a multicenter controlled study of 5 sc injections of 20 mg HEPP vs placebo in 140 patients.
Preliminary analyses suggest that the pentapeptide, HEPP, may provide a new therapeutic modality in the treatment of atopic allergic disease.
Article PDF
Author information
Authors and Affiliations
Rights and permissions
About this article
Cite this article
Hamburger, R., O'Connor, R. RESULTS OF DOUBLE-BLIND RANDOMLY SELECTED PLACEBO CONTROLLED THERAPEUTIC TRIALS OF HUMAN IgE PENTAPEPTIDE (HEPP). Pediatr Res 18 (Suppl 4), 256 (1984). https://doi.org/10.1203/00006450-198404001-00977
Issue Date:
DOI: https://doi.org/10.1203/00006450-198404001-00977